← All companies
NEOGENOMICS INC
NEO - CIK 0001077183
Market cap$1.47 B
Rank#2329
SEC filings1,246
NEOGENOMICS INC trades as NEO and has a market capitalization of $1.47 B, making it the #2329 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $727.33M, up 10.1% from the prior year and net income of -$108.00M. This page tracks NEOGENOMICS INC through 1,246 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$727.33MFY 2025
Net income (latest FY)-$108.00MFY 2025
Operating cash flow (latest FY)$5.23MFY 2025
Total assets (latest FY)$1.36BFY 2025
Gross margin43.2%latest FY
Net margin-14.8%latest FY
Financial performance
Over the last 9 fiscal years NEOGENOMICS INC's revenue grew from $231.81M to $727.33M, a compound annual growth rate of 13.5%. Net profit margin compressed from -2.6% to -14.8% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.47 B
- Share price (derived)market cap / shares outstanding
- $11.28
- EPS (diluted)FY 2015
- $-0.04
- Shares outstandingas of 2026-04-24
- 0.13B
- Total equityas of 2026-03-31
- $828.76M
- Return on equity
- -13.0%
- Long-term debtas of 2025-12-31
- $341.86M
- Cash & equivalentsas of 2026-03-31
- $146.14M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-13 |
| Insider trade | 4 | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-07 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
Recent press releases
- NeoGenomics Reports First Quarter 2026 Results2026-04-28
NeoGenomics Reports First Quarter 2026 Results :: NeoGenomics, Inc. (NEO)
- NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration2026-04-23
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
- NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 20262026-04-07
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
- NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling2026-03-16
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
- NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types2026-02-25
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types :: NeoGenomics, Inc. (NEO)
Similar companies
The largest companies sharing NEOGENOMICS INC's SEC industry classification (services-testing laboratories).
Frequently asked questions
What is NEOGENOMICS INC's market cap?
NEOGENOMICS INC (NEO) has a market capitalization of $1.47 B as of 2026-06-11, ranking #2329 among US-listed companies.
How much revenue does NEOGENOMICS INC make?
NEOGENOMICS INC reported revenue of $727.33M for fiscal year 2025, an increase of 10.1% year over year.
Is NEOGENOMICS INC profitable?
In its latest fiscal year NEOGENOMICS INC reported a net loss of $108.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.